Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah H. Gralnek
Observed name:
Sarah Gralnek
Institution:
University of Kansas Medical Center
Observed institution:
University of Kansas Medical Center
ORCID:
0009-0004-5229-7552
Observed ORCID:
0009-0004-5229-7552
OpenAlex ID:
A5094209261
Targeting neutrophil extracellular trap accumulation under flow in patients with immune-mediated thrombotic thrombocytopenic purpura
2024
·
Noritaka Yada
, Quan Zhang
, et al.
·
Blood Advances
·
23
PDF
Clinical Utility of Recently Food and Drug Administration-Approved IntelliSep Test (Sepsis Biomarker) for Early Diagnosis of Sepsis: Comparison with Other Biomarkers
2024
·
Nima Sarani
, Amitava Dasgupta
, et al.
·
Journal of Clinical Medicine
·
8
Assays for Plasma ADAMTS13 Activity and Inhibitors Using Recombinant FRETS-VWF73 Peptide
2026
·
Sarah H. Gralnek
, Szumam Liu
, et al.
·
Methods in molecular biology
·
1
Pre-infusion ADAMTS13 and VWF levels are associated with clinical outcomes of patients receiving CAR-T cell therapy
2025
·
Abdalla Shoaib
, Sarah Gralnek
, et al.
·
Blood
·
1
Clinical Utility of Recently FDA Approved IntelliSep test (Sepsis biomarker) for early Diagnosis of Sepsis: Comparison with other Biomarkers and von Willebrand Factor/ADAMTS13 Ration
2024
·
Hanan Elsarraj
, Nima Sarani
, et al.
·
American Journal of Clinical Pathology
·
1
PDF
73 Clinical Utility of Recently FDA-Approved QScoutTM Point-of-care Analyzer for Rapid Screening of Sepsis Patient: Comparison With Other Biomarkers and von Willebrand Factor/ADAMTS13 Ratio
2026
·
Molly Walkenhorst
, Nima Sarani
, et al.
·
American Journal of Clinical Pathology
PDF
Show more works
View as search
Works count:
6
Citation count:
34
H-index:
2
I10-index:
1
Year
Topic
Type